<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01926028</url>
  </required_header>
  <id_info>
    <org_study_id>NDV3A-003</org_study_id>
    <nct_id>NCT01926028</nct_id>
  </id_info>
  <brief_title>Safety, Tolerability, Immunogenicity and Efficacy of NDV-3A Vaccine in Preventing Recurrent Vulvovaginal Candidiasis</brief_title>
  <official_title>Phase 1b/2a, Multi-center, Double-blind, Randomized, Placebo-controlled Study of a Single Dose of NDV-3A or NDV-3 Vaccine to Evaluate Safety, Tolerability, Immunogenicity and Efficacy in Preventing Recurrent Vulvovaginal Candidiasis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>NovaDigm Therapeutics, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>NovaDigm Therapeutics, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a multi-center, randomized, double-blind, placebo-controlled study intended to assess
      the safety, tolerability and humoral and cellular immune response over a 12-month period
      after receiving one dose of either the NDV-3A vaccine, NDV-3 vaccine, or placebo. In
      addition, the clinical efficacy of NDV-3A vaccine in lowering the recurrence rate of
      vulvovaginal candidiasis (VVC) in patients with recurrent VVC (RVVC) will be evaluated
      relative to placebo.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The purpose of the Phase 1b portion of this study is to compare the NDV-3A vaccine, the NDV-3
      vaccine and the placebo head-to-head in the patient population of interest (women with RVVC)
      to evaluate safety and immunogenicity. The study size for comparing safety and immunogenicity
      (N=15 per group) is based on the dose comparison design used in study NDV3-001 (clinical
      trials.gov Identifier NCT01273922).

      The primary purpose of the Phase 2a portion of this study is to further evaluate safety,
      tolerability, and immunogenicity of the NDV-3A vaccine compared to placebo in a patient
      population of interest (women with RVVC). The secondary purpose is to determine whether the
      NDV-3A vaccine decreases the recurrence rate of VVC in 18-50 year old women with RVVC when
      compared to placebo. The study size for evaluating efficacy (N=87 per group) is based on
      assuming a 50% rate of VVC recurrences over the 6 month post-vaccination period in the
      placebo group and a 50% vaccine efficacy.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2013</start_date>
  <completion_date type="Actual">May 2016</completion_date>
  <primary_completion_date type="Actual">May 2015</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Summary of Injection Site Reactions for the Safety Population Over the 12-months Post Vaccination Period</measure>
    <time_frame>12-month</time_frame>
    <description>Summary of injection site reactions for the safety population over the 12-months post-vaccination period in the NDV-3A vaccine group, the NDV-3 vaccine group, and the placebo group.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Patients &lt;40 Years Old Who Were Recurrence-free Over the 12-month Post-vaccination Period</measure>
    <time_frame>12 months</time_frame>
    <description>Number of patients &lt;40 years old with documented RVVC who were recurrence-free over the 12-month post-vaccination period in the NDV-3A vaccine group and the placebo group</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Patients Who Were Recurrence-free Over the 12-month Post-vaccination Period</measure>
    <time_frame>12 months</time_frame>
    <description>Number of patients with documented RVVC who were recurrence-free over the 12-month post-vaccination period in the NDV-3A vaccine group and the placebo group</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to First VVC Episode From Study Day 17 to 360 - Participants &lt;40 Years Old</measure>
    <time_frame>12 months</time_frame>
    <description>Time-to-onset of first VVC episode from Study Day 17 for the NDV-3A vaccine group and the placebo group</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to First VVC Episode From Study Day 17 to 360 - All Participants</measure>
    <time_frame>12 months</time_frame>
    <description>Time-to-onset of first VVC episode from Study Day 17 for the NDV-3A vaccine group and the placebo group</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum Anti-Als3 IgG Titers Over the 12-month Post-vaccination Period</measure>
    <time_frame>0, 14, 28, 90, 180 and 360 days</time_frame>
    <description>Serum anti-Als3 IgG titers will be measured by ELISA at pre-defined time points over the 12-month post-vaccination period in the NDV-3A vaccine group, the NDV-3 vaccine group, and the placebo group.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum Anti-Als3 IgA1 Titers Over the 12-month Post-vaccination Period</measure>
    <time_frame>0, 14, 28, 90, 180 and 360 days</time_frame>
    <description>Serum anti-Als3 IgA1 titers will be measured by ELISA at pre-defined time points over the 12-month post-vaccination period in the NDV-3A vaccine group, the NDV-3 vaccine group, and the placebo group.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cervicovaginal Wash Anti-Als3 IgG Titers Over the 12-month Post-vaccination Period</measure>
    <time_frame>0, 14, 28, 90, 180 and 360 days</time_frame>
    <description>Cervicovaginal wash anti-Als3 IgG titers will be measured by ELISA at pre-defined time points over the 12-month post-vaccination period in the NDV-3A vaccine group, the NDV-3 vaccine group, and the placebo group.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cervicovaginal Wash Anti-Als3 IgA1 Titers Over the 12-month Post-vaccination Period</measure>
    <time_frame>0, 14, 28, 90, 180 and 360 days</time_frame>
    <description>Cervicovaginal wash anti-Als3 IgA1 titers will be measured by ELISA at pre-defined time points over the 12-month post-vaccination period in the NDV-3A vaccine group, the NDV-3 vaccine group, and the placebo group.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Als3-specific T-cell Production of Interferon Gamma Over the Post-vaccination Period</measure>
    <time_frame>0, 14, 90 days</time_frame>
    <description>Als3-specific T-cell production of interferon gamma will be measured by enzyme-linked immunospot (ELISpot) at pre-defined time points over the 12-month post-vaccination period in the NDV-3A vaccine group, the NDV-3 vaccine group, and the placebo group.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Als3-specific T-cell Production of Interleukin-17A Over the Post-vaccination Period</measure>
    <time_frame>0, 14, 90 days</time_frame>
    <description>Als3-specific T-cell production of interleukin-17A will be measured by enzyme-linked immunospot (ELISpot) at pre-defined time points over the 12-month post-vaccination period in the NDV-3A vaccine group, the NDV-3 vaccine group, and the placebo group.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">188</enrollment>
  <condition>Vulvovaginal Candidiasis</condition>
  <arm_group>
    <arm_group_label>NDV-3A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Experimental Vaccine: a purified, recombinant antigen (rAls3) formulated with aluminum hydroxide adjuvant</description>
  </arm_group>
  <arm_group>
    <arm_group_label>NDV-3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Experimental Vaccine: a purified, recombinant antigen (rAls3 with 6-His tag) formulated with aluminum hydroxide adjuvant</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo: aluminum hydroxide adjuvant</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>NDV-3A</intervention_name>
    <description>0.5mL injection IM</description>
    <arm_group_label>NDV-3A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>NDV-3</intervention_name>
    <description>0.5mL injection IM</description>
    <arm_group_label>NDV-3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>aluminum hydroxide and buffered saline</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Has been informed of the nature of the study and has agreed to and is able to read,
             review, and sign the informed consent document prior to Screening.

          -  Is a female between 18-50 years of age, inclusive, at the time of vaccination on an
             acceptable form of birth control.

          -  Has a current episode of VVC (at Screening/Day -14) that can be confirmed with acute
             signs and symptoms of VVC (Composite Questionnaire score of â‰¥3) and a positive vaginal
             mycological culture for C. albicans.

          -  Has a history of 2 or more documented episodes of VVC in the 12 months prior to
             Screening, including at least one of the previous episodes confirmed by positive
             results from a diagnostic lab test specific for the presence of Candida. Additional
             episodes may be self-reported.

          -  Has a normal Papanicolaou (Pap) smear from the previous 12 months, or has no
             clinically significant abnormalities on a Pap smear taken at study entry as judged and
             documented by the investigator(s).

          -  Is in general good health as judged and documented by the investigator(s)

        Exclusion Criteria:

          -  Reports receiving any systemic or topical vaginal antifungal therapy for 4 weeks prior
             to study entry.

          -  Mycological results from Study Day -14 or earlier cultures taken within 4 weeks prior
             to vaccination that show other yeast species (e.g., C. glabrata, C. tropicalis, etc.)
             as the cause of vaginitis.

          -  Has other active infectious cause(s) of vulvovaginitis (e.g., bacterial vaginosis,
             Trichomonas vaginalis, Chlamydia trachomatis, Neisseria gonorrhea, symptomatic Herpes
             Simplex Virus-1 (HSV-1), symptomatic HSV-2, or symptomatic human papilloma virus) at
             Screening or other vaginal or vulvar conditions that would confound the interpretation
             of clinical response as judged by the investigator(s).

          -  Will be under treatment or surgery at the start of the study for cervical
             intraepithelial neoplasia (CIN) or cervical carcinoma.

          -  Reports any presence or history of a clinically significant disorder involving the
             cardiovascular, respiratory, renal, gastrointestinal, immunologic, hematologic,
             endocrine, or neurologic system(s), diagnosed diabetes mellitus (controlled or not) or
             psychiatric disease that would confound the interpretation of clinical response as
             judged by the investigator(s).

          -  Reports a history of allergic response(s) or other serious reactions to nickel,
             aluminum, or yeast products

          -  Reports a history of clinically significant allergies including food or drug
             allergies, anaphylaxis (or other serious reaction) to vaccines.

          -  Has a known history of or active infection with hepatitis B, hepatitis C, or human
             immunodeficiency virus (HIV).

          -  Reports receiving or planning to receive any investigational drug, investigational
             vaccine, or investigational device within 4 weeks prior to vaccination, and at any
             other time during their participation in the study.

          -  Reports receiving or planning to receive any other live vaccine within 3 weeks prior
             to vaccination and for 3 weeks after vaccination.

          -  Reports having or shows evidence of a recent history of drug or alcohol abuse.

          -  Reports the use or planned use of any immunosuppressive drugs, including systemic or
             topical vaginal corticosteroids, within 4 weeks prior to vaccination, with the
             exception of topical steroids (e.g., Over-The-Counter hydrocortisone) used elsewhere
             on the body.

          -  Reports the use or planned use of any medications or treatments that may alter immune
             responses to the study vaccine within 3 weeks prior to vaccination

          -  Reports receiving any blood products within 3 months prior to vaccination and
             throughout the study.

          -  Reports donating blood/plasma within 4 weeks prior to vaccination.

          -  Is pregnant or intends to become pregnant over the course of the study, breastfeeding,
             or has any other medical and/or social (e.g., non-compliant) reason which, in the
             opinion of the investigator(s), would prevent participation in the study.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>John P. Hennessey, Jr., Ph.D.</last_name>
    <role>Study Director</role>
    <affiliation>NovaDigm Therapeutics, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Precision Trials LLC</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85032</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Arkansas Women's Center</name>
      <address>
        <city>Little Rock</city>
        <state>Arkansas</state>
        <zip>72205</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Women's Health Care Research Corp</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92123</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>McCann MD Research, Inc.</name>
      <address>
        <city>Torrance</city>
        <state>California</state>
        <zip>90505</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Women's Medical Research Group, LLC</name>
      <address>
        <city>Clearwater</city>
        <state>Florida</state>
        <zip>33759</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>KO Clinical Research, LLC</name>
      <address>
        <city>Fort Lauderdale</city>
        <state>Florida</state>
        <zip>33316</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Community Medical Research</name>
      <address>
        <city>Miami Beach</city>
        <state>Florida</state>
        <zip>33141</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Miami Clinical Research, LLC</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33155</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Community Medical Research LLC</name>
      <address>
        <city>North Miami</city>
        <state>Florida</state>
        <zip>33181</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MedPharmics</name>
      <address>
        <city>Metairie</city>
        <state>Louisiana</state>
        <zip>70006</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>WSU Physician's Group</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Saginaw Valley Medical Research Group, LLC</name>
      <address>
        <city>Saginaw</city>
        <state>Michigan</state>
        <zip>48604</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lawrence OB/Gyn Clinical Research</name>
      <address>
        <city>Lawrenceville</city>
        <state>New Jersey</state>
        <zip>08648</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SUNY Downstate Medical Center</name>
      <address>
        <city>Brooklyn</city>
        <state>New York</state>
        <zip>11203</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Suffolk Ob/Gyn</name>
      <address>
        <city>Port Jefferson</city>
        <state>New York</state>
        <zip>11777</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Drexel University College of Medicine</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19102</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Magnolia OB/GYN Research Center, LLC</name>
      <address>
        <city>Myrtle Beach</city>
        <state>South Carolina</state>
        <zip>29752</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Advanced Research Associates</name>
      <address>
        <city>Corpus Christi</city>
        <state>Texas</state>
        <zip>78414</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Discovery Clinical Trials- HCWC, LLC</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75231</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>TMC Life Research</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77054</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.novadigmtherapeutics.com</url>
    <description>Company Web Site</description>
  </link>
  <verification_date>June 2018</verification_date>
  <study_first_submitted>August 9, 2013</study_first_submitted>
  <study_first_submitted_qc>August 16, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 20, 2013</study_first_posted>
  <results_first_submitted>May 23, 2018</results_first_submitted>
  <results_first_submitted_qc>May 23, 2018</results_first_submitted_qc>
  <results_first_posted type="Actual">June 20, 2018</results_first_posted>
  <last_update_submitted>June 22, 2018</last_update_submitted>
  <last_update_submitted_qc>June 22, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">July 18, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>recurrent vulvovaginal candidiasis</keyword>
  <keyword>candida</keyword>
  <keyword>NDV3</keyword>
  <keyword>vaginal thrush</keyword>
  <keyword>chronic yeast infection</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Candidiasis</mesh_term>
    <mesh_term>Candidiasis, Vulvovaginal</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Presentations at scientific meetings and publication</ipd_description>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Placebo</title>
          <description>Placebo: aluminum hydroxide and buffered saline
Placebo: 0.5 mL injection IM</description>
        </group>
        <group group_id="P2">
          <title>NDV-3A</title>
          <description>Experimental Vaccine: a purified, recombinant antigen (rAls3) formulated with aluminum hydroxide adjuvant
NDV-3A: 0.5mL injection IM</description>
        </group>
        <group group_id="P3">
          <title>NDV-3</title>
          <description>Experimental Vaccine: a purified, recombinant antigen (rAls3 with 6-His tag) formulated with aluminum hydroxide adjuvant
NDV-3: 0.5mL injection IM</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="85"/>
                <participants group_id="P2" count="89"/>
                <participants group_id="P3" count="14"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="64"/>
                <participants group_id="P2" count="67"/>
                <participants group_id="P3" count="12"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="21"/>
                <participants group_id="P2" count="22"/>
                <participants group_id="P3" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="5"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="9"/>
                <participants group_id="P3" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Non compliance or other reasons</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Placebo</title>
          <description>Placebo: aluminum hydroxide adjuvant
Placebo: 0.5 mL injection IM</description>
        </group>
        <group group_id="B2">
          <title>NDV-3A</title>
          <description>Experimental Vaccine: a purified, recombinant antigen (rAls3) formulated with aluminum hydroxide adjuvant
NDV-3A: 0.5mL injection IM</description>
        </group>
        <group group_id="B3">
          <title>NDV-3</title>
          <description>Experimental Vaccine: a purified, recombinant antigen (rAls3 with 6-His tag) formulated with aluminum hydroxide adjuvant
NDV-3: 0.5mL injection IM</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="85"/>
            <count group_id="B2" value="89"/>
            <count group_id="B3" value="14"/>
            <count group_id="B4" value="188"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="32.4" spread="8.80"/>
                    <measurement group_id="B2" value="32.1" spread="8.82"/>
                    <measurement group_id="B3" value="35.4" spread="10.70"/>
                    <measurement group_id="B4" value="32.5" spread="8.95"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="85"/>
                    <measurement group_id="B2" value="89"/>
                    <measurement group_id="B3" value="14"/>
                    <measurement group_id="B4" value="188"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="27"/>
                    <measurement group_id="B2" value="36"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="66"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="58"/>
                    <measurement group_id="B2" value="53"/>
                    <measurement group_id="B3" value="11"/>
                    <measurement group_id="B4" value="122"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="17"/>
                    <measurement group_id="B2" value="19"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="38"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="64"/>
                    <measurement group_id="B2" value="68"/>
                    <measurement group_id="B3" value="12"/>
                    <measurement group_id="B4" value="144"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="85"/>
                    <measurement group_id="B2" value="89"/>
                    <measurement group_id="B3" value="14"/>
                    <measurement group_id="B4" value="188"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Summary of Injection Site Reactions for the Safety Population Over the 12-months Post Vaccination Period</title>
        <description>Summary of injection site reactions for the safety population over the 12-months post-vaccination period in the NDV-3A vaccine group, the NDV-3 vaccine group, and the placebo group.</description>
        <time_frame>12-month</time_frame>
        <population>All enrolled patients.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo: aluminum hydroxide adjuvant
Placebo: 0.5 mL injection IM</description>
          </group>
          <group group_id="O2">
            <title>NDV-3A</title>
            <description>Experimental Vaccine: a purified, recombinant antigen (rAls3) formulated with aluminum hydroxide adjuvant
NDV-3A: 0.5mL injection IM</description>
          </group>
          <group group_id="O3">
            <title>NDV-3</title>
            <description>Experimental Vaccine: a purified, recombinant antigen (rAls3 with 6-His tag) formulated with aluminum hydroxide adjuvant
NDV-3: 0.5mL injection IM</description>
          </group>
        </group_list>
        <measure>
          <title>Summary of Injection Site Reactions for the Safety Population Over the 12-months Post Vaccination Period</title>
          <description>Summary of injection site reactions for the safety population over the 12-months post-vaccination period in the NDV-3A vaccine group, the NDV-3 vaccine group, and the placebo group.</description>
          <population>All enrolled patients.</population>
          <units>AEs</units>
          <param>Count of Units</param>
          <units_analyzed>AEs</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="85"/>
                <count group_id="O2" value="89"/>
                <count group_id="O3" value="14"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>AEs</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="279"/>
                <count group_id="O2" value="358"/>
                <count group_id="O3" value="31"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Patients with &gt;= 1 injection site reaction</title>
                  <measurement_list>
                    <measurement group_id="O1" value="72"/>
                    <measurement group_id="O2" value="79"/>
                    <measurement group_id="O3" value="10"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Induration</title>
                  <measurement_list>
                    <measurement group_id="O1" value="25"/>
                    <measurement group_id="O2" value="46"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Pain</title>
                  <measurement_list>
                    <measurement group_id="O1" value="56"/>
                    <measurement group_id="O2" value="70"/>
                    <measurement group_id="O3" value="7"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Redness</title>
                  <measurement_list>
                    <measurement group_id="O1" value="34"/>
                    <measurement group_id="O2" value="45"/>
                    <measurement group_id="O3" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Swelling</title>
                  <measurement_list>
                    <measurement group_id="O1" value="28"/>
                    <measurement group_id="O2" value="47"/>
                    <measurement group_id="O3" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Tenderness</title>
                  <measurement_list>
                    <measurement group_id="O1" value="64"/>
                    <measurement group_id="O2" value="71"/>
                    <measurement group_id="O3" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Patients &lt;40 Years Old Who Were Recurrence-free Over the 12-month Post-vaccination Period</title>
        <description>Number of patients &lt;40 years old with documented RVVC who were recurrence-free over the 12-month post-vaccination period in the NDV-3A vaccine group and the placebo group</description>
        <time_frame>12 months</time_frame>
        <population>Participants &lt;40 years old</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo: aluminum hydroxide adjuvant
Placebo: 0.5mL injection IM</description>
          </group>
          <group group_id="O2">
            <title>NDV-3A</title>
            <description>Experimental Vaccine: a purified, recombinant antigen (rAls3) formulated with aluminum hydroxide adjuvant
NDV-3A: 0.5mL injection IM</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients &lt;40 Years Old Who Were Recurrence-free Over the 12-month Post-vaccination Period</title>
          <description>Number of patients &lt;40 years old with documented RVVC who were recurrence-free over the 12-month post-vaccination period in the NDV-3A vaccine group and the placebo group</description>
          <population>Participants &lt;40 years old</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="50"/>
                <count group_id="O2" value="57"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11"/>
                    <measurement group_id="O2" value="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Equivalence</non_inferiority_type>
            <non_inferiority_desc>The proportion of patients in each group was summarized with point estimates and their 95% confidence interval</non_inferiority_desc>
            <p_value>0.03</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
            <param_type>Cox Proportional Hazard</param_type>
            <param_value>0.39</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.17</ci_lower_limit>
            <ci_upper_limit>0.91</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Patients Who Were Recurrence-free Over the 12-month Post-vaccination Period</title>
        <description>Number of patients with documented RVVC who were recurrence-free over the 12-month post-vaccination period in the NDV-3A vaccine group and the placebo group</description>
        <time_frame>12 months</time_frame>
        <population>All participants</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo: aluminum hydroxide adjuvant
Placebo: 0.5mL injection IM</description>
          </group>
          <group group_id="O2">
            <title>NDV-3A</title>
            <description>Experimental Vaccine: a purified, recombinant antigen (rAls3) formulated with aluminum hydroxide adjuvant
NDV-3A: 0.5mL injection IM</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients Who Were Recurrence-free Over the 12-month Post-vaccination Period</title>
          <description>Number of patients with documented RVVC who were recurrence-free over the 12-month post-vaccination period in the NDV-3A vaccine group and the placebo group</description>
          <population>All participants</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="68"/>
                <count group_id="O2" value="74"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17"/>
                    <measurement group_id="O2" value="28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Equivalence</non_inferiority_type>
            <non_inferiority_desc>The proportion of patients in each group was summarized with point estimates and their 95% confidence interval</non_inferiority_desc>
            <p_value>0.10</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
            <param_type>Cox Proportional Hazard</param_type>
            <param_value>0.55</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.27</ci_lower_limit>
            <ci_upper_limit>1.13</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to First VVC Episode From Study Day 17 to 360 - Participants &lt;40 Years Old</title>
        <description>Time-to-onset of first VVC episode from Study Day 17 for the NDV-3A vaccine group and the placebo group</description>
        <time_frame>12 months</time_frame>
        <population>Participants &lt; 40 years old</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo: aluminum hydroxide adjuvant
Placebo: 0.5mL injection IM</description>
          </group>
          <group group_id="O2">
            <title>NDV-3A</title>
            <description>Experimental Vaccine: a purified, recombinant antigen (rAls3) formulated with aluminum hydroxide adjuvant
NDV-3A: 0.5mL injection IM</description>
          </group>
        </group_list>
        <measure>
          <title>Time to First VVC Episode From Study Day 17 to 360 - Participants &lt;40 Years Old</title>
          <description>Time-to-onset of first VVC episode from Study Day 17 for the NDV-3A vaccine group and the placebo group</description>
          <population>Participants &lt; 40 years old</population>
          <units>Days</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="50"/>
                <count group_id="O2" value="57"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="105" lower_limit="45" upper_limit="325"/>
                    <measurement group_id="O2" value="210" lower_limit="95" upper_limit="360"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to First VVC Episode From Study Day 17 to 360 - All Participants</title>
        <description>Time-to-onset of first VVC episode from Study Day 17 for the NDV-3A vaccine group and the placebo group</description>
        <time_frame>12 months</time_frame>
        <population>All participants</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo: aluminum hydroxide adjuvant
Placebo: 0.5mL injection IM</description>
          </group>
          <group group_id="O2">
            <title>NDV-3A</title>
            <description>Experimental Vaccine: a purified, recombinant antigen (rAls3) formulated with aluminum hydroxide adjuvant
NDV-3A: 0.5mL injection IM</description>
          </group>
        </group_list>
        <measure>
          <title>Time to First VVC Episode From Study Day 17 to 360 - All Participants</title>
          <description>Time-to-onset of first VVC episode from Study Day 17 for the NDV-3A vaccine group and the placebo group</description>
          <population>All participants</population>
          <units>Days</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="68"/>
                <count group_id="O2" value="74"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="135" lower_limit="50" upper_limit="330"/>
                    <measurement group_id="O2" value="175" lower_limit="70" upper_limit="350"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Serum Anti-Als3 IgG Titers Over the 12-month Post-vaccination Period</title>
        <description>Serum anti-Als3 IgG titers will be measured by ELISA at pre-defined time points over the 12-month post-vaccination period in the NDV-3A vaccine group, the NDV-3 vaccine group, and the placebo group.</description>
        <time_frame>0, 14, 28, 90, 180 and 360 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo: aluminum hydroxide adjuvant
Placebo: 0.5mL injection IM</description>
          </group>
          <group group_id="O2">
            <title>NDV-3A</title>
            <description>Experimental Vaccine: a purified, recombinant antigen (rAls3) formulated with aluminum hydroxide adjuvant
NDV-3A: 0.5mL injection IM</description>
          </group>
          <group group_id="O3">
            <title>NDV-3</title>
            <description>Experimental Vaccine: a purified, recombinant antigen (rAls3 with 6-His tag) formulated with aluminum hydroxide adjuvant
NDV-3: 0.5mL injection IM</description>
          </group>
        </group_list>
        <measure>
          <title>Serum Anti-Als3 IgG Titers Over the 12-month Post-vaccination Period</title>
          <description>Serum anti-Als3 IgG titers will be measured by ELISA at pre-defined time points over the 12-month post-vaccination period in the NDV-3A vaccine group, the NDV-3 vaccine group, and the placebo group.</description>
          <units>Titer (dilution^-1)</units>
          <param>Geometric Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="85"/>
                <count group_id="O2" value="89"/>
                <count group_id="O3" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 0</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="465" spread="3.3"/>
                    <measurement group_id="O2" value="434" spread="3.5"/>
                    <measurement group_id="O3" value="305" spread="3.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 14</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="464" spread="3.6"/>
                    <measurement group_id="O2" value="37381" spread="3.9"/>
                    <measurement group_id="O3" value="18078" spread="4.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 28</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="419" spread="3.3"/>
                    <measurement group_id="O2" value="31459" spread="3.6"/>
                    <measurement group_id="O3" value="13674" spread="4.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 90</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="447" spread="3.2"/>
                    <measurement group_id="O2" value="17818" spread="3.5"/>
                    <measurement group_id="O3" value="10868" spread="3.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 180</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="523" spread="3.5"/>
                    <measurement group_id="O2" value="10852" spread="3.5"/>
                    <measurement group_id="O3" value="6297" spread="3.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 360</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="371" spread="3.6"/>
                    <measurement group_id="O2" value="5349" spread="3.2"/>
                    <measurement group_id="O3" value="4999" spread="3.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Serum Anti-Als3 IgA1 Titers Over the 12-month Post-vaccination Period</title>
        <description>Serum anti-Als3 IgA1 titers will be measured by ELISA at pre-defined time points over the 12-month post-vaccination period in the NDV-3A vaccine group, the NDV-3 vaccine group, and the placebo group.</description>
        <time_frame>0, 14, 28, 90, 180 and 360 days</time_frame>
        <population>All participants</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo: aluminum hydroxide adjuvant
Placebo: 0.5mL injection IM</description>
          </group>
          <group group_id="O2">
            <title>NDV-3A</title>
            <description>Experimental Vaccine: a purified, recombinant antigen (rAls3) formulated with aluminum hydroxide adjuvant
NDV-3A: 0.5mL injection IM</description>
          </group>
          <group group_id="O3">
            <title>NDV-3</title>
            <description>Experimental Vaccine: a purified, recombinant antigen (rAls3 with 6-His tag) formulated with aluminum hydroxide adjuvant
NDV-3: 0.5mL injection IM</description>
          </group>
        </group_list>
        <measure>
          <title>Serum Anti-Als3 IgA1 Titers Over the 12-month Post-vaccination Period</title>
          <description>Serum anti-Als3 IgA1 titers will be measured by ELISA at pre-defined time points over the 12-month post-vaccination period in the NDV-3A vaccine group, the NDV-3 vaccine group, and the placebo group.</description>
          <population>All participants</population>
          <units>Titer (dilution^-1)</units>
          <param>Geometric Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="85"/>
                <count group_id="O2" value="89"/>
                <count group_id="O3" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 0</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="937" spread="5.6"/>
                    <measurement group_id="O2" value="1011" spread="5.5"/>
                    <measurement group_id="O3" value="657" spread="3.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 14</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="954" spread="6.4"/>
                    <measurement group_id="O2" value="63834" spread="5.1"/>
                    <measurement group_id="O3" value="44866" spread="3.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 28</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="850" spread="5.5"/>
                    <measurement group_id="O2" value="43557" spread="5.2"/>
                    <measurement group_id="O3" value="30118" spread="3.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 90</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1062" spread="6.0"/>
                    <measurement group_id="O2" value="23053" spread="5.1"/>
                    <measurement group_id="O3" value="20349" spread="3.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 180</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="982" spread="7.3"/>
                    <measurement group_id="O2" value="18215" spread="5.9"/>
                    <measurement group_id="O3" value="14633" spread="3.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 360</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="563" spread="7.3"/>
                    <measurement group_id="O2" value="8727" spread="5.8"/>
                    <measurement group_id="O3" value="12357" spread="3.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Cervicovaginal Wash Anti-Als3 IgG Titers Over the 12-month Post-vaccination Period</title>
        <description>Cervicovaginal wash anti-Als3 IgG titers will be measured by ELISA at pre-defined time points over the 12-month post-vaccination period in the NDV-3A vaccine group, the NDV-3 vaccine group, and the placebo group.</description>
        <time_frame>0, 14, 28, 90, 180 and 360 days</time_frame>
        <population>All participants</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo: aluminum hydroxide adjuvant
Placebo: 0.5mL injection IM</description>
          </group>
          <group group_id="O2">
            <title>NDV-3A</title>
            <description>Experimental Vaccine: a purified, recombinant antigen (rAls3) formulated with aluminum hydroxide adjuvant
NDV-3A: 0.5mL injection IM</description>
          </group>
          <group group_id="O3">
            <title>NDV-3</title>
            <description>Experimental Vaccine: a purified, recombinant antigen (rAls3 with 6-His tag) formulated with aluminum hydroxide adjuvant
NDV-3: 0.5mL injection IM</description>
          </group>
        </group_list>
        <measure>
          <title>Cervicovaginal Wash Anti-Als3 IgG Titers Over the 12-month Post-vaccination Period</title>
          <description>Cervicovaginal wash anti-Als3 IgG titers will be measured by ELISA at pre-defined time points over the 12-month post-vaccination period in the NDV-3A vaccine group, the NDV-3 vaccine group, and the placebo group.</description>
          <population>All participants</population>
          <units>Titer (dilution^-1)</units>
          <param>Geometric Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="85"/>
                <count group_id="O2" value="89"/>
                <count group_id="O3" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 0</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.03" spread="5.27"/>
                    <measurement group_id="O2" value="1.93" spread="4.19"/>
                    <measurement group_id="O3" value="1.47" spread="4.69"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 14</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.93" spread="5.15"/>
                    <measurement group_id="O2" value="20.67" spread="6.28"/>
                    <measurement group_id="O3" value="8.01" spread="8.09"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 28</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.44" spread="3.63"/>
                    <measurement group_id="O2" value="24.98" spread="6.97"/>
                    <measurement group_id="O3" value="9.88" spread="14.49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 90</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.40" spread="3.97"/>
                    <measurement group_id="O2" value="14.28" spread="6.16"/>
                    <measurement group_id="O3" value="5.28" spread="4.11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 180</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.66" spread="4.55"/>
                    <measurement group_id="O2" value="7.68" spread="6.73"/>
                    <measurement group_id="O3" value="2.72" spread="6.42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 360</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.44" spread="5.14"/>
                    <measurement group_id="O2" value="4.36" spread="6.39"/>
                    <measurement group_id="O3" value="2.76" spread="6.12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Cervicovaginal Wash Anti-Als3 IgA1 Titers Over the 12-month Post-vaccination Period</title>
        <description>Cervicovaginal wash anti-Als3 IgA1 titers will be measured by ELISA at pre-defined time points over the 12-month post-vaccination period in the NDV-3A vaccine group, the NDV-3 vaccine group, and the placebo group.</description>
        <time_frame>0, 14, 28, 90, 180 and 360 days</time_frame>
        <population>All participants</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo: aluminum hydroxide adjuvant
Placebo: 0.5mL injection IM</description>
          </group>
          <group group_id="O2">
            <title>NDV-3A</title>
            <description>Experimental Vaccine: a purified, recombinant antigen (rAls3) formulated with aluminum hydroxide adjuvant
NDV-3A: 0.5mL injection IM</description>
          </group>
          <group group_id="O3">
            <title>NDV-3</title>
            <description>Experimental Vaccine: a purified, recombinant antigen (rAls3 with 6-His tag) formulated with aluminum hydroxide adjuvant
NDV-3: 0.5mL injection IM</description>
          </group>
        </group_list>
        <measure>
          <title>Cervicovaginal Wash Anti-Als3 IgA1 Titers Over the 12-month Post-vaccination Period</title>
          <description>Cervicovaginal wash anti-Als3 IgA1 titers will be measured by ELISA at pre-defined time points over the 12-month post-vaccination period in the NDV-3A vaccine group, the NDV-3 vaccine group, and the placebo group.</description>
          <population>All participants</population>
          <units>Titer (dilution^-1)</units>
          <param>Geometric Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="85"/>
                <count group_id="O2" value="89"/>
                <count group_id="O3" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 0</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.86" spread="6.37"/>
                    <measurement group_id="O2" value="5.16" spread="5.38"/>
                    <measurement group_id="O3" value="2.02" spread="6.81"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 14</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.99" spread="7.89"/>
                    <measurement group_id="O2" value="53.65" spread="7.00"/>
                    <measurement group_id="O3" value="28.24" spread="6.86"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 28</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.44" spread="4.51"/>
                    <measurement group_id="O2" value="45.96" spread="8.56"/>
                    <measurement group_id="O3" value="22.22" spread="9.61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 90</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.87" spread="4.89"/>
                    <measurement group_id="O2" value="22.52" spread="7.50"/>
                    <measurement group_id="O3" value="5.75" spread="6.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 180</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.13" spread="5.60"/>
                    <measurement group_id="O2" value="17.74" spread="5.76"/>
                    <measurement group_id="O3" value="10.17" spread="4.83"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 360</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.39" spread="5.05"/>
                    <measurement group_id="O2" value="9.32" spread="7.06"/>
                    <measurement group_id="O3" value="5.02" spread="7.41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Als3-specific T-cell Production of Interferon Gamma Over the Post-vaccination Period</title>
        <description>Als3-specific T-cell production of interferon gamma will be measured by enzyme-linked immunospot (ELISpot) at pre-defined time points over the 12-month post-vaccination period in the NDV-3A vaccine group, the NDV-3 vaccine group, and the placebo group.</description>
        <time_frame>0, 14, 90 days</time_frame>
        <population>All participants</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo: aluminum hydroxide adjuvant
Placebo: 0.5mL injection IM</description>
          </group>
          <group group_id="O2">
            <title>NDV-3A</title>
            <description>Experimental Vaccine: a purified, recombinant antigen (rAls3) formulated with aluminum hydroxide adjuvant
NDV-3A: 0.5mL injection IM</description>
          </group>
          <group group_id="O3">
            <title>NDV-3</title>
            <description>Experimental Vaccine: a purified, recombinant antigen (rAls3 with 6-His tag) formulated with aluminum hydroxide adjuvant
NDV-3: 0.5mL injection IM</description>
          </group>
        </group_list>
        <measure>
          <title>Als3-specific T-cell Production of Interferon Gamma Over the Post-vaccination Period</title>
          <description>Als3-specific T-cell production of interferon gamma will be measured by enzyme-linked immunospot (ELISpot) at pre-defined time points over the 12-month post-vaccination period in the NDV-3A vaccine group, the NDV-3 vaccine group, and the placebo group.</description>
          <population>All participants</population>
          <units>Spot Forming Units</units>
          <param>Geometric Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="85"/>
                <count group_id="O2" value="89"/>
                <count group_id="O3" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 0</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.7" spread="3.0"/>
                    <measurement group_id="O2" value="3.6" spread="3.3"/>
                    <measurement group_id="O3" value="2.6" spread="3.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 14</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.0" spread="3.2"/>
                    <measurement group_id="O2" value="22.8" spread="5.3"/>
                    <measurement group_id="O3" value="22.1" spread="7.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 90</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.2" spread="3.5"/>
                    <measurement group_id="O2" value="16.6" spread="4.6"/>
                    <measurement group_id="O3" value="15.1" spread="4.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Als3-specific T-cell Production of Interleukin-17A Over the Post-vaccination Period</title>
        <description>Als3-specific T-cell production of interleukin-17A will be measured by enzyme-linked immunospot (ELISpot) at pre-defined time points over the 12-month post-vaccination period in the NDV-3A vaccine group, the NDV-3 vaccine group, and the placebo group.</description>
        <time_frame>0, 14, 90 days</time_frame>
        <population>All Participants</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo: aluminum hydroxide adjuvant
Placebo: 0.5mL injection IM</description>
          </group>
          <group group_id="O2">
            <title>NDV-3A</title>
            <description>Experimental Vaccine: a purified, recombinant antigen (rAls3) formulated with aluminum hydroxide adjuvant
NDV-3A: 0.5mL injection IM</description>
          </group>
          <group group_id="O3">
            <title>NDV-3</title>
            <description>Experimental Vaccine: a purified, recombinant antigen (rAls3 with 6-His tag) formulated with aluminum hydroxide adjuvant
NDV-3: 0.5mL injection IM</description>
          </group>
        </group_list>
        <measure>
          <title>Als3-specific T-cell Production of Interleukin-17A Over the Post-vaccination Period</title>
          <description>Als3-specific T-cell production of interleukin-17A will be measured by enzyme-linked immunospot (ELISpot) at pre-defined time points over the 12-month post-vaccination period in the NDV-3A vaccine group, the NDV-3 vaccine group, and the placebo group.</description>
          <population>All Participants</population>
          <units>Spot Forming Units</units>
          <param>Geometric Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="85"/>
                <count group_id="O2" value="89"/>
                <count group_id="O3" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 0</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.4" spread="4.1"/>
                    <measurement group_id="O2" value="4.2" spread="4.4"/>
                    <measurement group_id="O3" value="5.2" spread="4.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 14</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.6" spread="3.4"/>
                    <measurement group_id="O2" value="9.6" spread="5.3"/>
                    <measurement group_id="O3" value="11.1" spread="5.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 90</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.9" spread="3.5"/>
                    <measurement group_id="O2" value="6.6" spread="3.9"/>
                    <measurement group_id="O3" value="3.3" spread="3.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>12-months</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Placebo</title>
          <description>Placebo: aluminum hydroxide adjuvant
Placebo: 0.5mL injection IM</description>
        </group>
        <group group_id="E2">
          <title>NDV-3A</title>
          <description>Experimental Vaccine: a purified, recombinant antigen (rAls3) formulated with aluminum hydroxide adjuvant
NDV-3A: 0.5mL injection IM</description>
        </group>
        <group group_id="E3">
          <title>NDV-3</title>
          <description>Experimental Vaccine: a purified, recombinant antigen (rAls3 with 6-His tag) formulated with aluminum hydroxide adjuvant
NDV-3: 0.5mL injection IM</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>4</frequency_threshold>
        <default_vocab>MedDRA (10.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="48" subjects_at_risk="85"/>
                <counts group_id="E2" subjects_affected="35" subjects_at_risk="89"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anemia</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="85"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Vaginitis bacterial</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="85"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="89"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="85"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="89"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="85"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="89"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="85"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="89"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="85"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="89"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Chief Scientific Officer</name_or_title>
      <organization>NovaDigm Therapeutics, Inc.</organization>
      <phone>2676405189</phone>
      <email>john_hennessey@novadigm.net</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

